Sandrine Aspeslagh

4.4k total citations · 1 hit paper
89 papers, 2.5k citations indexed

About

Sandrine Aspeslagh is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sandrine Aspeslagh has authored 89 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 27 papers in Immunology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sandrine Aspeslagh's work include Cancer Immunotherapy and Biomarkers (49 papers), Immune Cell Function and Interaction (17 papers) and CAR-T cell therapy research (13 papers). Sandrine Aspeslagh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (49 papers), Immune Cell Function and Interaction (17 papers) and CAR-T cell therapy research (13 papers). Sandrine Aspeslagh collaborates with scholars based in Belgium, France and United States. Sandrine Aspeslagh's co-authors include Sophie Postel‐Vinay, Jean‐Charles Soria, Aurélien Marabelle, Daphné Morel, Daniel Jeffery, Geneviève Almouzni, Laurence Zitvogel, Sylvie Rusakiewicz, Dirk Elewaut and Astrid De Meulenaere and has published in prestigious journals such as SHILAP Revista de lepidopterología, The EMBO Journal and Blood.

In The Last Decade

Sandrine Aspeslagh

83 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise

2019 313 citations Daphné Morel, Daniel Jeffery et al. Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandrine Aspeslagh Belgium	26	1.4k	843	661	345	227	89	2.5k
Young H. Kim United States	29	919 0.6×	898 1.1×	547 0.8×	525 1.5×	233 1.0×	77	2.5k
Daniel Sanghoon Shin United States	19	1.7k 1.2×	1.3k 1.5×	971 1.5×	324 0.9×	131 0.6×	35	2.8k
Robert Yuan United States	8	1.0k 0.7×	794 0.9×	666 1.0×	376 1.1×	144 0.6×	10	1.9k
Kenneth F. Grossmann United States	27	1.2k 0.9×	435 0.5×	997 1.5×	517 1.5×	209 0.9×	95	2.3k
Sangeeta Goswami United States	19	1.2k 0.8×	1.2k 1.5×	801 1.2×	626 1.8×	113 0.5×	57	2.7k
Jermaine Coward Australia	23	1.2k 0.9×	404 0.5×	704 1.1×	380 1.1×	156 0.7×	87	2.3k
Rahul Ladwa Australia	16	986 0.7×	519 0.6×	525 0.8×	365 1.1×	146 0.6×	93	1.7k
Soizic Garaud Belgium	26	1.3k 0.9×	1.3k 1.5×	578 0.9×	293 0.8×	92 0.4×	64	2.4k
Dominik Rüttinger Germany	25	1.3k 0.9×	1.3k 1.5×	696 1.1×	415 1.2×	165 0.7×	57	2.7k
Yuping Sun China	27	1.3k 0.9×	831 1.0×	818 1.2×	502 1.5×	100 0.4×	87	2.4k

Countries citing papers authored by Sandrine Aspeslagh

Since Specialization

Citations

This map shows the geographic impact of Sandrine Aspeslagh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandrine Aspeslagh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandrine Aspeslagh more than expected).

Fields of papers citing papers by Sandrine Aspeslagh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandrine Aspeslagh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandrine Aspeslagh. The network helps show where Sandrine Aspeslagh may publish in the future.

Co-authorship network of co-authors of Sandrine Aspeslagh

This figure shows the co-authorship network connecting the top 25 collaborators of Sandrine Aspeslagh. A scholar is included among the top collaborators of Sandrine Aspeslagh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandrine Aspeslagh. Sandrine Aspeslagh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mariette, Xavier, Sven Borchmann, Sandrine Aspeslagh, et al.. (2025). Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 11(1). e005033–e005033. 1 indexed citations

Aspeslagh, Sandrine, et al.. (2024). Immunotherapy efficacy and toxicity: Reviewing the evidence behind patient implementable strategies. European Journal of Cancer. 209. 114235–114235. 3 indexed citations

Xavier, Catarina, Johannes Heemskerk, Nick Devoogdt, et al.. (2023). Phase I Study of [⁶⁸Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I). Journal of Nuclear Medicine. 64(9). 1378–1384. 26 indexed citations

Mariette, Xavier, Sven Borchmann, Sandrine Aspeslagh, et al.. (2023). POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS. Annals of the Rheumatic Diseases. 82. 707–708. 2 indexed citations

Jauregui-Amezaga, Aranzazu, Sandrine Aspeslagh, Jeroen Dekervel, et al.. (2023). Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus. European Journal of Cancer. 187. 36–57. 6 indexed citations

Mebis, Jeroen, et al.. (2023). Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report. European Heart Journal - Case Reports. 7(3). ytad112–ytad112.

Rembielak, Agata, Thomas Yau, Baran Akagündüz, et al.. (2023). Recommendations of the International Society of Geriatric Oncology on skin cancer management in older patients. Journal of Geriatric Oncology. 14(4). 101502–101502. 10 indexed citations

Bravenboer, Bert, et al.. (2023). Immunosuppressive therapy management in cancer patients with autoimmune diseases treated with immune checkpoint inhibitors: A case series and systematic literature review. Journal of Oncology Pharmacy Practice. 30(1). 55–66. 1 indexed citations

Jaeghere, Emiel A. De, Sandra Tuyaerts, Ann Belmans, et al.. (2022). 2022-RA-638-ESGO Pembrolizumab with multimodal immunomodulation in chemotherapy-pretreated cervical, endometrial, and uterine cancer: the PRIMMO phase II trial. International Journal of Gynecological Cancer. 32. A187–A188.

10.

Aspeslagh, Sandrine, et al.. (2022). Isolated adrenocorticotropic hormone deficiency and sialadenitis associated with nivolumab: a case report. Journal of Medical Case Reports. 16(1). 456–456. 5 indexed citations

11.

Filette, Jeroen de, S. André, Sandrine Aspeslagh, et al.. (2022). Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms. BMC Endocrine Disorders. 22(1). 291–291. 4 indexed citations

12.

Pappot, Helle, Sandrine Aspeslagh, Anne Rogiers, et al.. (2021). Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study. European Journal of Cancer. 157. 225–237. 16 indexed citations

13.

Morel, Daphné, Daniel Jeffery, Sandrine Aspeslagh, Geneviève Almouzni, & Sophie Postel‐Vinay. (2019). Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise. Nature Reviews Clinical Oncology. 17(2). 91–107. 313 indexed citations breakdown →

14.

Gauci, Marie-Léa, Émilie Lanoy, Stéphane Champiat, et al.. (2018). Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research. 25(3). 946–956. 106 indexed citations

15.

Aspeslagh, Sandrine, Eduardo Castañón, Valérie Dyevre, et al.. (2018). Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. European Journal of Cancer. 95. 68–74. 20 indexed citations

16.

Aspeslagh, Sandrine, Daphné Morel, Jean‐Charles Soria, & Sophie Postel‐Vinay. (2018). Epigenetic modifiers as new immunomodulatory therapies in solid tumours. Annals of Oncology. 29(4). 812–824. 64 indexed citations

17.

Castañón, Eduardo, Valérie Dyevre, Sandrine Aspeslagh, et al.. (2017). Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience. Annals of Oncology. 28. v413–v413. 1 indexed citations

18.

Verlingue, Loïc, Christophe Massard, Antoine Hollebecque, et al.. (2016). Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients. Annals of Oncology. 27. vi38–vi38. 3 indexed citations

19.

Aspeslagh, Sandrine & Aurélien Marabelle. (2015). Defining the Role of a Novel Immune Checkpoint Modulator: Anti-OX40. 2016(1).

20.

Fostier, Karel, Sandrine Aspeslagh, Wim Renmans, et al.. (2013). Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model. PLoS ONE. 8(5). e65075–e65075. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact